Scilex Holding has announced a successful conclusion to its end-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) regarding SP-103, a next-generation, triple-strength formulation of ZTlido, designed for the treatment of chronic neck pain associated with muscle spasms. The meeting has clarified the path forward for SP-103 towards a New Drug Application (NDA) submission, contingent on the successful completion of Phase III clinical trials.
Clinical and Commercial Potential
According to independent market research conducted by Syneos Health Consulting, SP-103 demonstrates substantial market potential, with projected peak sales reaching $1.2 billion annually within six years post-launch. This projection underscores the significant unmet need for effective and innovative treatments for chronic neck pain.
Addressing Unmet Needs in Pain Management
Dmitri Lissin, M.D., Chief Medical Officer of Scilex, stated, "We are very pleased with the end of Phase II meeting and received a clear path forward to NDA for our blockbuster product candidate, SP-103... We are looking forward to conducting Phase 3 trials and believe that Scilex is the only company with technology allowing much higher lidocaine concentration than any other topical lidocaine system treatments. Higher concentration of a drug per covered area of skin is important for achieving therapeutic response."
SP-103: A Novel Approach
SP-103 represents a novel approach to topical pain management, leveraging a higher concentration of lidocaine compared to existing treatments. This increased concentration aims to enhance therapeutic efficacy in alleviating chronic neck pain and associated muscle spasms. The Phase III trials will be crucial in validating these potential benefits and confirming the safety profile of SP-103.
